Background and purpose
Infection with HPV16, a high-risk human papillomavirus (HPV), can cause cervical cancer in humans. These infections carry a high risk of morbidity and mortality among women worldwide. This study aimed to perform an in vivo comparison of poly(D,L-lactic acid-glycolide conjugate) (PLGA)-encapsulated peptide mixture nanoparticles and PLGA microspheres as a vaccine delivery system.
method
PLGA polymer was used to form microspheres for a therapeutic vaccine against cervical cancer. Target antigens were L1 and L2 capsid proteins from HPV16 and E6 and E7 oncoproteins. These antigens were selected based on their immunogenicity, allergenicity, and toxicity. We predicted epitopes on cytotoxic T lymphocytes (CTLs) and helper T lymphocytes. For CTL epitope studies, we used synthetic chimeric PLGA microsphere peptides consisting of multiple H-2Db-restricted HPV16 peptides in combination with other immune-enhancing adjuvants predicted in our study.
result
Upon subcutaneous administration of H-2Db-restricted HPV16 peptide, CTLs were able to eliminate in vitro TC-1 tumor cells expressing HPV16 E6 and E7. Furthermore, TC-1 cells protected C57BL/6 mice from in vivo challenge. To address this issue, peptide-based vaccines, one of the most effective vaccine systems, have been extensively studied. The combination of peptide-based vaccination with microsphere peptide mixture particles and delivery technology increases the effectiveness of stimulating cellular immune responses and eliminating tumor cells.
conclusion
This approach may provide a potential therapeutic candidate vaccine based on microsphere-encapsulated peptides for the prevention of cervical cancer caused by HPV.
sauce:
Reference magazines:
Kern, MA et al. (2024). Human papillomavirus type 16-based L1, L2, E6, and E7 peptide microspheres induce encapsulated peptide mixture-specific cytotoxic T lymphocytes and tumor regression in a mouse model of cervical cancer . Cancer screening and prevention. doi.org/10.14218/csp.2024.00003.
